Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.

Markus Menzen,Tina Landsvig Berentzen,Andrei-Mircea Catarig,Sebastian Pieperhoff,Jörg Simon,Stephan Jacob

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association（2023）

引用 5|浏览4

暂无评分

摘要

In a real-world population in Germany, patients with type 2 diabetes treated with once-weekly semaglutide experienced clinically significant improvements in glycaemic control and body weight. These results support the use of once-weekly semaglutide in routine clinical practice in adult patients with type 2 diabetes in Germany.

查看译文

关键词

blood pressure,clinical practice,patient-reported outcomes,real-world evidence,glucagon-like peptide-1 receptor agonist

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要